Registry‐Based Analysis of Treatment and Retreatment Attacks of Hereditary Angioedema
Authors:
- Roman HaklRHRoman Hakl
- Jan BarošJBJan Baroš
- Marta SobotkováMSMarta Sobotková
- Radana ZachováRZRadana Zachová
- Pavlína KrálíčkováPKPavlína Králíčková
- Martina VachováMVMartina Vachová
- Irena KrčmováIKIrena Krčmová
- Michal SvobodaMSMichal Svoboda
- Vendula SzmucováVSVendula Szmucová
- Monika SkotákováMSMonika Skotáková
- Jiří LitzmanJLJiří Litzman
Open Access
- 7 June 2026
- journal article
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (8) , 986-988
Abstract
Summary: Retreatment occurs in approximately 15% of treated hereditary angioedema attacks in real‐world practice. Abdominal attacks, multisite involvement and treatment choice are associated with retreatment occurrence.Keywords
This publication has 7 references indexed in Scilit:
- The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and updateAllergy, 2022
- Treatment of hereditary angioedema with icatibant: Efficacy in clinical trials versus effectiveness in the real-world settingAllergy and Asthma Proceedings, 2014
- Pasteurized and Nanofiltered, Plasma-Derived C1 Esterase Inhibitor Concentrate for the Treatment of Hereditary AngioedemaImmunotherapy, 2014
- Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label studyAllergy, 2013
- Efficacy and safety of recombinant human C1‐inhibitor for the treatment of attacks of hereditary angioedema: European open‐label extension studyClinical & Experimental Allergy, 2012
- Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trialAnnals of Allergy, Asthma & Immunology, 2011
- Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary AngioedemaNew England Journal of Medicine, 2010